Literature DB >> 25432728

Drug-induced movement disorders.

Shyamal H Mehta1, John C Morgan2, Kapil D Sethi3.   

Abstract

Movement disorders are frequently a result of prescription drugs or of illicit drug use. This article focuses on prescribed drugs but briefly mentions drugs of abuse. The main emphasis is on movement disorders caused by dopamine receptor-blocking agents. However, movement disorders caused by other drugs are also briefly discussed.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dopamine receptor; Drugs; Movement disorder; Tardive Dystonia; Tardive dyskinesia

Mesh：

Substances：

Year:  2015        PMID： 25432728     DOI： 10.1016/j.ncl.2014.09.011

Source DB:  PubMed          Journal:  Neurol Clin        ISSN： 0733-8619            Impact factor:   3.806


  14 in total

1.  Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia.

Authors:  Jiajun Weng; Yan Zhang; Huafang Li; Yifeng Shen; Wenjuan Yu
Journal:  Gen Psychiatr       Date:  2019-02-23

2.  A new knock-in mouse model of l-DOPA-responsive dystonia.

Authors:  Samuel J Rose; Xin Y Yu; Ann K Heinzer; Porter Harrast; Xueliang Fan; Robert S Raike; Valerie B Thompson; Jean-Francois Pare; David Weinshenker; Yoland Smith; Hyder A Jinnah; Ellen J Hess
Journal:  Brain       Date:  2015-07-27       Impact factor: 13.501

Review 3.  Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Authors:  Nicki Niemann; Joseph Jankovic
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

Review 4.  The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis.

Authors:  Melissa Lau Moon Lin; Paula D Robinson; Jacqueline Flank; Lillian Sung; L Lee Dupuis
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

5.  Dopamine Receptor Agonist Treatment of Idiopathic Dystonia: A Reappraisal in Humans and Mice.

Authors:  Xueliang Fan; Yuping Donsante; H A Jinnah; Ellen J Hess
Journal:  J Pharmacol Exp Ther       Date:  2018-01-18       Impact factor: 4.030

6.  Cell-intrinsic effects of TorsinA(ΔE) disrupt dopamine release in a mouse model of TOR1A dystonia.

Authors:  Anthony M Downs; Xueliang Fan; Radhika F Kadakia; Yuping Donsante; H A Jinnah; Ellen J Hess
Journal:  Neurobiol Dis       Date:  2021-04-21       Impact factor: 5.996

Review 7.  Post-stroke dyskinesias.

Authors:  Mohammad Obadah Nakawah; Eugene C Lai
Journal:  Neuropsychiatr Dis Treat       Date:  2016-11-07       Impact factor: 2.570

8.  Response to: A Commentary on "Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders".

Authors:  Stéphane Potvin; Andràs Tikàsz
Journal:  Front Behav Neurosci       Date:  2015-08-12       Impact factor: 3.558

Review 9.  Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology.

Authors:  Josip Anđelo Borovac
Journal:  Yale J Biol Med       Date:  2016-03-24

10.  Development and clinimetric assessment of a nurse-administered screening tool for movement disorders in psychosis.

Authors:  Bettina Balint; Helen Killaspy; Louise Marston; Thomas Barnes; Anna Latorre; Eileen Joyce; Caroline S Clarke; Rosa De Micco; Mark J Edwards; Roberto Erro; Thomas Foltynie; Rachael M Hunter; Fiona Nolan; Anette Schrag; Nick Freemantle; Yvonne Foreshaw; Nicholas Green; Kailash P Bhatia; Davide Martino
Journal:  BJPsych Open       Date:  2018-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.